Modular Medical Inc

Modular Medical Inc (MODD) Stock Analysis

$1.330

+0.052 (+3.91%)At close

Loading chart…
High
1.455
Open
1.360
VWAP
1.35
Volume
54.69K
Mkt Cap
50.76M
Low
1.255
Amount
73.65K
EV/EBITDA, TTM
0.00

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body.

AI analysis of Modular Medical Inc (MODD)

Sell

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

Valuation Metrics

The current forward P/E ratio for Modular Medical Inc (MODD) is 0.00, compared to its 5-year average forward P/E of -2.57.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.57
Current P/E
0.00
Overvalued
-1.37
Undervalued
-3.77

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Fair
5Y Average P/S
136.48
Current P/S
3.80
Overvalued
395.58
Undervalued
-122.61

Events Timeline

2026-10-15 (ET)

09:30:00

Modular Medical Launches Digital Education Resources for Diabetes Patients

2026-09-04 (ET)

08:30:00

Modular Medical Secures Contract with U.S. National Pharmacy Benefit Manager

2026-09-03 (ET)

08:30:00

Modular Medical Receives FDA Approval for Software Enhancements

2026-08-03 (ET)

08:30:00

Modular Medical Plans to Launch Tubeless Patch Pump in Five U.S. Markets in October 2026

2026-07-23 (ET)

08:30:00

Modular Medical Forms Pivot Innovation Council

News

MODD FAQ — answered by Alphio AI

Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Modular Medical Inc (MODD) is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $1.33, with an RSI of 24.997 indicating it is oversold. The company has reported a staggering year-to-date change of -88.48% and a 1-year change of -91.30%, reflecting severe declines in stock value. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the continued negative net income, which reached -7,790,000 USD in Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading